| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.IJROBP.2007.10.053 |
| P698 | PubMed publication ID | 18164849 |
| P50 | author | Suresh Senan | Q37830477 |
| Berend J Slotman | Q40690934 | ||
| P2093 | author name string | Egbert F Smit | |
| Cornelis J A Haasbeek | |||
| Frank J Lagerwaard | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lung cancer | Q47912 |
| P304 | page(s) | 685-692 | |
| P577 | publication date | 2007-12-31 | |
| P1433 | published in | International Journal of Radiation Oncology Biology Physics | Q2296252 |
| P1476 | title | Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer | |
| P478 | volume | 70 |
| Q40224314 | 4D radiobiological modelling of the interplay effect in conventionally and hypofractionated lung tumour IMRT. |
| Q38778226 | A Histologic Basis for the Efficacy of SBRT to the lung |
| Q36554195 | A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927). |
| Q28079625 | A critical review of recent developments in radiotherapy for non-small cell lung cancer |
| Q48312990 | A dosimetric parameter to limit chest wall toxicity in SABR of NSCLC. |
| Q57282826 | A matched-pair analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer versus early stage non-small cell lung cancer |
| Q83366949 | A method for improved verification of entire IMRT plans by film dosimetry |
| Q44011535 | A prospective study of quality of life including fatigue and pulmonary function after stereotactic body radiotherapy for medically inoperable early-stage lung cancer |
| Q42010143 | A study on the influence of breathing phases in intensity-modulated radiotherapy of lung tumours using four-dimensional CT |
| Q39771088 | A survey of stereotactic body radiotherapy use in the United States |
| Q38790915 | A systematic review of outcomes following stereotactic ablative radiotherapy in the treatment of early-stage primary lung cancer |
| Q35200640 | Alternative to surgery in early stage NSCLC-interventional radiologic approaches |
| Q37767616 | Alternatives to surgery for early stage non-small cell lung cancer-ready for prime time? |
| Q47160015 | An evaluation of websites providing patient information on stereotactic body radiation therapy (SBRT) for stage I lung cancer in three Western European countries |
| Q64269417 | Anemia is a poor prognostic factor for stage I non-small cell lung cancer (NSCLC) patients treated with Stereotactic Body Radiation Therapy (SBRT) |
| Q55251898 | Angiotensin-converting Enzyme Inhibitors Decrease the Incidence of Radiation-induced Pneumonitis Among Lung Cancer Patients: A Systematic Review and Meta-analysis. |
| Q28083924 | Challenges in the treatment of early non-small cell lung cancer: what is the standard, what are the challenges and what is the future for radiotherapy? |
| Q64266974 | Changes in quality of life after surgery or radiotherapy in early-stage lung cancer |
| Q55354282 | Chronic obstructive pulmonary disease: a complex comorbidity of lung cancer. |
| Q36241457 | Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer |
| Q59125770 | Clinical outcomes following advanced respiratory motion management (respiratory gating or dynamic tumor tracking) with stereotactic body radiation therapy for stage I non-small-cell lung cancer |
| Q42030396 | Clinical practice patterns of lung stereotactic body radiation therapy in the United States: a secondary analysis |
| Q35812234 | Comparative effectiveness of surgery and radiosurgery for stage I non-small cell lung cancer |
| Q38914996 | Comparison of the Effectiveness of Radiofrequency Ablation With Stereotactic Body Radiation Therapy in Inoperable Stage I Non-Small Cell Lung Cancer: A Systemic Review and Pooled Analysis. |
| Q47105967 | Complication probability for radiation pneumonitis (RP) after stereotactic body radiotherapy (SBRT). |
| Q26995851 | Complications from Stereotactic Body Radiotherapy for Lung Cancer |
| Q42116312 | Cone-beam computed tomography in lung stereotactic ablative radiation therapy: predictive parameters of early response |
| Q89869712 | Contrast enhanced oesophageal avoidance for stereotactic body radiotherapy: Barium vs. Gastrografin |
| Q37468265 | Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer |
| Q41872325 | Developing and evaluating stereotactic lung RT trials: what we should know about the influence of inhomogeneity corrections on dose |
| Q60908706 | Developments in Stereotactic Body Radiotherapy |
| Q61446980 | Dose prescription with spatial uncertainty for peripheral lung SBRT |
| Q42321832 | Dosimetric evaluation of the impacts of different heterogeneity correction algorithms on target doses in stereotactic body radiation therapy for lung tumors |
| Q37789035 | Early detection and screening of lung cancer |
| Q64969902 | Early stage lung cancer survival after wedge resection and stereotactic body radiation. |
| Q27015651 | Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice |
| Q37392508 | Extracranial stereotactic body radiotherapy. Review of main SBRT features and indications in primary tumors |
| Q55001587 | Feasibility of stereotactic body radiotherapy for locally-advanced non-small cell lung cancer. |
| Q47868427 | Feasibility of using single photon counting X-ray for lung tumor position estimation based on 4D-CT. |
| Q92859947 | Four-dimensional computed tomography-based biomechanical measurements of pulmonary function and their correlation with clinical outcome for lung stereotactic body radiation therapy patients |
| Q90115551 | Hypofractionated 192Ir source stereotactic ablative brachytherapy with coplanar template assistance in the primary treatment of peripheral lung cancer |
| Q37601085 | Hypofractionated 3D radiotherapy for inoperable T1-3 N0-1 non-small-cell lung cancer |
| Q36555940 | Hypofractionated radiotherapy for primary or secondary oligometastatic lung cancer using Tomotherapy |
| Q52716524 | Image-based management of empiric lung stereotactic body radiotherapy (SBRT) without biopsy: Predictors from a 10-year single institution experience. |
| Q27025204 | Imaging techniques for tumour delineation and heterogeneity quantification of lung cancer: overview of current possibilities |
| Q35074232 | Impact of tumor attachment to the pleura measured by a pretreatment CT image on outcome of stage I NSCLC treated with stereotactic body radiotherapy |
| Q38705654 | Impacts of lung and tumor volumes on lung dosimetry for nonsmall cell lung cancer |
| Q50016239 | Improvement of conformal arc plans by using deformable margin delineation method for stereotactic lung radiotherapy. |
| Q49356566 | Incidence of rib fractures after stereotactic body radiotherapy for peripheral lung lesions: clinical experience and dose response estimation |
| Q89694316 | Independent review of 4DCT scans used for SABR treatment planning |
| Q40116176 | Influence of different treatment techniques and clinical factors over the intrafraction variation on lung stereotactic body radiotherapy. |
| Q47098978 | Initial clinical experience with stereotactic lung radiotherapy, based on a biological model-driven prescription method |
| Q26863239 | Innovative technologies in thoracic radiation therapy for lung cancer |
| Q47141026 | Institutional experience on the treatment of lung and liver lesions with stereotactic body radiotherapy and Novalis Exactrac Adaptive Gating technique |
| Q27016589 | Is radiofrequency ablation more effective than stereotactic ablative radiotherapy in patients with early stage medically inoperable non-small cell lung cancer? |
| Q26864983 | Is stereotactic ablative radiotherapy equivalent to sublobar resection in high-risk surgical patients with stage I non-small-cell lung cancer? |
| Q64997326 | Lobectomy versus stereotactic ablative radiotherapy for medically operable patients with stage IA non-small cell lung cancer: A virtual randomized phase III trial stratified by age. |
| Q93111716 | Long term outcome after 48 Gy stereotactic ablative body radiotherapy for peripheral stage I non-small cell lung cancer |
| Q37077160 | Long term survival with stereotactic ablative radiotherapy (SABR) versus thoracoscopic sublobar lung resection in elderly people: national population based study with propensity matched comparative analysis |
| Q37698823 | Low incidence of chest wall pain with a risk-adapted lung stereotactic body radiation therapy approach using three or five fractions based on chest wall dosimetry |
| Q35687174 | Minimal Inter-Fractional Fiducial Migration during Image-Guided Lung Stereotactic Body Radiotherapy Using SuperLock Nitinol Coil Fiducial Markers |
| Q40542033 | Multi-institutional experience of stereotactic body radiotherapy for large (≥5 centimeters) non-small cell lung tumors |
| Q34167597 | Non-surgical management of stage I lung cancer |
| Q36550894 | Optimizing the flattening filter free beam selection in RapidArc®-based stereotactic body radiotherapy for Stage I lung cancer |
| Q64276234 | Outcomes of stereotactic body radiotherapy versus lobectomy for stage I non-small cell lung cancer: a propensity score matching analysis |
| Q59587525 | Outcomes of stereotactic radiotherapy for a new clinical stage I lung cancer arising postpneumonectomy |
| Q38021143 | Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis |
| Q33627751 | Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904. |
| Q60908672 | Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma |
| Q64277127 | Phase II study of compensator-based non-coplanar intensity-modulated radiotherapy for Stage I non-small-cell lung cancer |
| Q36500564 | Predictors of radiotherapy induced bone injury (RIBI) after stereotactic lung radiotherapy. |
| Q26851601 | Primary Treatment Options for High-Risk/Medically Inoperable Early Stage NSCLC Patients |
| Q36840389 | Prognostic significance of centrosomal protein 55 in stage I pulmonary adenocarcinoma after radical resection |
| Q47735759 | Prospective evaluation of anxiety, depression and quality of life in medically inoperable early stage non-small cell lung cancer patients treated with stereotactic ablative radiotherapy. |
| Q26765355 | Radio(chemo)therapy in locally advanced nonsmall cell lung cancer |
| Q47714442 | Radiobiological analysis of stereotactic body radiation therapy for an evidence-based planning target volume of the lung using multiphase CT images obtained with a pneumatic abdominal compression apparatus: a case study |
| Q36363955 | Radiobiological modeling analysis of the optimal fraction scheme in patients with peripheral non-small cell lung cancer undergoing stereotactic body radiotherapy |
| Q37458027 | Radiobiological modeling of two stereotactic body radiotherapy schedules in patients with stage I peripheral non-small cell lung cancer |
| Q36753846 | Radiotherapy for a second primary lung cancer arising post-pneumonectomy: planning considerations and clinical outcomes. |
| Q57875955 | Radiothérapie en conditions stéréotaxiques des patients inopérables |
| Q40010886 | Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study |
| Q42072656 | Reirradiation of Pediatric Tumors Using Hypofractionated Stereotactic Radiotherapy |
| Q39135612 | SBRT for centrally localized NSCLC - What is too central? |
| Q37307675 | Salvage surgery for local failures after stereotactic ablative radiotherapy for early stage non-small cell lung cancer |
| Q38161371 | Scalpel or SABR for Treatment of Early-Stage Lung Cancer: Clinical Considerations for the Multidisciplinary Team |
| Q38994894 | Short report: interim safety results for a phase II trial measuring the integration of stereotactic ablative radiotherapy (SABR) plus surgery for early stage non-small cell lung cancer (MISSILE-NSCLC). |
| Q59587510 | Stage I nonsmall cell lung cancer in patients aged ≥75 years |
| Q40308740 | Stereotactic Ablative Radiation Therapy is Highly Safe and Effective for Elderly Patients With Early-stage Non-Small Cell Lung Cancer |
| Q40932457 | Stereotactic Body Radiotherapy (SBRT) with Lower Doses for Selected Patients with Stage I Non-small-cell Lung Cancer (NSCLC). |
| Q53062109 | Stereotactic Body Radiotherapy Versus Surgery for Medically Operable Stage I Non–Small-Cell Lung Cancer: A Markov Model–Based Decision Analysis |
| Q64956876 | Stereotactic MR-Guided Online Adaptive Radiation Therapy (SMART) for Ultracentral Thorax Malignancies: Results of a Phase 1 Trial. |
| Q37784902 | Stereotactic Radiosurgery for Lung Tumors |
| Q36286591 | Stereotactic ablative body radiotherapy (SABR) for primary and secondary lung tumours |
| Q35667834 | Stereotactic ablative radiotherapy (SABR) for lung cancer: What does the future hold? |
| Q41112569 | Stereotactic ablative radiotherapy (SABR) in operable early stage non-small cell lung cancer (NSCLC) patients: challenge to claim being undisputed gold standard |
| Q44020055 | Stereotactic ablative radiotherapy for small lung tumors with a moderate dose. Favorable results and low toxicity |
| Q35667829 | Stereotactic ablative radiotherapy for stage I NSCLC: Recent advances and controversies |
| Q35667866 | Stereotactic ablative radiotherapy for stage I NSCLC: Successes and existing challenges |
| Q37127178 | Stereotactic ablative radiotherapy in the UK: current status and developments |
| Q30656342 | Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials |
| Q41834552 | Stereotactic body radiation therapy (SBRT) for early stage lung cancer delivers clinically significant radiation to the draining lymph nodes |
| Q47159050 | Stereotactic body radiation therapy (SBRT) for early stage lung cancer delivers clinically significant radiation to the draining lymph nodes |
| Q36550532 | Stereotactic body radiation therapy for a new lung cancer arising after pneumonectomy: dosimetric evaluation and pulmonary toxicity |
| Q37652546 | Stereotactic body radiation therapy for centrally-located lung tumors |
| Q34010065 | Stereotactic body radiation therapy for inoperable early stage lung cancer |
| Q36105945 | Stereotactic body radiation therapy for patients with lung cancer previously treated with thoracic radiation |
| Q37420376 | Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer |
| Q64096283 | Stereotactic body radiation therapy in early-stage NSCLC: historical review, contemporary evidence and future implications |
| Q64917835 | Stereotactic body radiotherapy for centrally-located lung tumors with 56 Gy in seven fractions: A retrospective study. |
| Q35143839 | Stereotactic body radiotherapy for early-stage non-small cell lung cancer: clinical outcomes from a National Patient Registry |
| Q37222099 | Stereotactic body radiotherapy for stage I lung cancer and small lung metastasis: evaluation of an immobilization system for suppression of respiratory tumor movement and preliminary results |
| Q49356651 | Stereotactic body radiotherapy for stage I non-small cell lung cancer |
| Q37527522 | Stereotactic radiation therapy for inoperable, early-stage non-small-cell lung cancer |
| Q35824255 | Stereotactic radiotherapy for early stage non-small cell lung cancer |
| Q47159062 | Summary of the lecture given on June 1, 2017 on the occasion of the Jacob I. Fabrikant Award ceremony |
| Q47106372 | Surgery compared to stereotactic body radiation therapy for early-stage non-small cell lung cancer: better, equivalent or worse? |
| Q26863046 | Surgery in 2013 and beyond |
| Q38224998 | The role of percutaneous image-guided ablation for lung tumors |
| Q35113011 | The role of stereotactic ablative radiotherapy for early-stage and oligometastatic non-small cell lung cancer: evidence for changing paradigms |
| Q37743289 | The role of stereotactic body radiotherapy in the management of non-small cell lung cancer: an emerging standard for the medically inoperable patient? |
| Q36642258 | The use of isodose levels to interpret radiation induced lung injury: a quantitative analysis of computed tomography changes |
| Q37589200 | Treatment advances for medically inoperable non-small-cell lung cancer: emphasis on prospective trials |
| Q26853124 | Treatment of early stage non-small cell lung cancer: surgery or stereotactic ablative radiotherapy? |
| Q38110978 | Treatment of early-stage lung cancer detected by screening: surgery or stereotactic ablative radiotherapy? |
| Q93369476 | Tumor Control and Toxicity after SBRT for Ultracentral, Central, and Paramediastinal Lung Tumors |
| Q43112508 | Use of FDG-PET to guide dose prescription heterogeneity in stereotactic body radiation therapy for lung cancers with volumetric modulated arc therapy: a feasibility study |
| Q30461426 | Volumetric modulated arc therapy: a review of current literature and clinical use in practice. |
| Q38172228 | What would be the most appropriate α/β ratio in the setting of stereotactic body radiation therapy for early stage non-small cell lung cancer |
| Q53321521 | [Radiofrequency ablation of primary lung cancer: a single centre experience] |
Search more.